Anti-HMGCR myopathy: Diversity of clinical presentations in a national cohort in New Zealand.

Autor: Chow KL; Department of Immunology, Canterbury Health Laboratories, Christchurch, New Zealand; Department of Immunology, NSW Health Pathology, Newcastle, NSW, Australia. Electronic address: ke.chow@health.nsw.gov.au., Keating PE; Department of Immunology, Canterbury Health Laboratories, Christchurch, New Zealand., Solanki K; Department of Rheumatology, Waikato Hospital, Hamilton, New Zealand., Sapsford M; Department of Rheumatology, Middlemore Hospital, Auckland, New Zealand., Lindsay K; Department of Immunology, Auckland City Hospital, Auckland, New Zealand; Department of Rheumatology, Auckland City Hospital, Auckland, New Zealand., O'Donnell JL; Department of Immunology, Canterbury Health Laboratories, Christchurch, New Zealand.
Jazyk: angličtina
Zdroj: Seminars in arthritis and rheumatism [Semin Arthritis Rheum] 2024 Oct; Vol. 68, pp. 152522. Date of Electronic Publication: 2024 Jul 14.
DOI: 10.1016/j.semarthrit.2024.152522
Abstrakt: Aims: We describe the varied clinical presentations, barriers in diagnosis and outcomes of anti-HMGCR myopathy in a large national cohort.
Methods: Adults found positive for serum anti-HMGCR autoantibodies via line blot or enzyme-immunoassay followed by immunoprecipitation were included in the study.
Results: Of 75 patients identified, the records of 72 (96 %) described weakness as the presenting symptom. The records of 65 gave a reliable description of proximal weakness. In 22/65 (33.8 %) the weakness was described as predominantly or solely lower limb weakness. Forty-five of 75 (60 %) presented with a subacute onset (duration of symptoms >4 weeks -≤6 months), whilst 22/75 (29.3 %) presented with a more indolent chronic onset (duration of symptoms >6 months). Eighteen of 75 (24 %) suffered falls and 2/75 (2.7 %) had "general decline". In three patients no weakness was described: two presented with myalgia and one with a skin rash characterized as Jessner lymphocytic skin rash. Median creatine kinase at presentation was 7337 U/L (range 1050-25,500). Muscle biopsy was performed in 38 (50.7 %). Associated malignancy was infrequent. Four patients recovered without immunosuppression. Five-year and 10-year survival was 92.7 % (95 % CI 80.6-97.4 %), and 82.5 % (95 % CI 61.2-92.8 %) respectively.
Conclusion: Recurrent falls, a long prodrome and dominant lower limb proximal weakness were common in this anti-HMGCR myopathy cohort. These features overlap with frailty syndrome and sporadic inclusion body myositis emphasizing the importance of considering anti-HMGCR myopathy in that clinical context. A minority of patients recover after statin withdrawal alone.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: